Target journal: Frontiers in Neurology (MedRxiv)

A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design and baseline data

- Gennaro Pagano^{1*}, Frank G Boess¹, Kirsten I Taylor^{1,2}, Benedicte Ricci³, Brit Mollenhauer^{4,5}, Werner Poewe⁶, Anne Boulay⁷, Judith Anzures-Cabrera⁸, Annamarie Voqt¹, Maddalena
- Marchesi³, Anke Post⁹, Tania Nikolcheva¹⁰, Gene G Kinney¹¹, Wagner M Zago¹¹, Daniel K
 Ness¹¹, Hanno Svoboda¹, Markus Britschgi¹, Susanne Ostrowitzki¹⁰, Tanya Simuni¹²,
- Kenneth Marek¹³, Martin Koller¹¹, Jeff Sevigny¹⁴, Rachelle Doody¹⁰, Paulo Fontoura¹⁰, Daniel
- 8 Umbricht¹, Azad Bonni¹, PASADENA Investigators and Prasinezumab Study Group
- 9 1. Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases
- Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland:
- 12 2. Faculty of Psychology, University of Basel, Basel, Switzerland;
- 13 3. Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche
- 14 Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland;
- 15 4. Paracelsus-Elena-Klinik, Kassel, Germany;
- 16 5. Department of Neurology, University Medical Center Göttingen, Göttingen, Germany;
- 17 6. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria;
- 18 7. Idorisa Pharmaceuticals Ltd, Allschwil, Switzerland;
- 19 8. Roche Products Ltd, Welwyn Garden City, UK;
- 20 9. Feetme SAS, Paris, France;
- 21 10. F. Hoffmann-La Roche Ltd, Basel, Switzerland;
- 22 11. Prothena Biosciences Inc, South San Francisco, CA, USA;
- 12. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL,
 USA;
- 25 13. Institute for Neurodegenerative Disorders, New Haven, CT, USA;
- 14. Prevail Therapeutics, New York, USA.
- 27 * Correspondence:

1

2

- 28 Corresponding author: Gennaro Pagano MD, PhD
- 29 Expert Medical Director & Group Leader in Neuroscience and Rare Diseases
- 30 Roche Pharma Research and Early Development (pRED)
- 31 F. Hoffmann-La Roche Ltd
- 32 Basel, Switzerland
- 33 Email: gennaro.pagano@roche.com

34

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

PASADENA investigators: Claudia Altendorf, Chareyna Anandan, Giulia Andrews, Solène Ansquer, 35 Raphaele Arrouasse, Sana Aslam, Jean-Philippe Azulay, Jeanette Baker, Ernest Balaquer Martinez, 36 Shadi Barbu, Kara Bardram, Danny Bega, Helena Bejr-Kasem Marco, Isabelle Benatru, Eve 37 Benchetrit, Felix Bernhard, Amir Besharat, Sagari Bette, Amelie Bichon, Andrew Billnitzer, Sophie 38 Blondeau, Thomas Boraud, Freiderike Borngräber, James Boyd, Kathrin Brockmann, Matthew 39 Brodsky, Ethan Brown, Christof Bruecke, Fabienne Calvas, Monica Canelo, Federico Carbone, Claire 40 Carroll, Laura Casado Fernandez, Catherine Cassé-Perrot, Anna Castrioto, Helene Catala, Justine 41 Chan, Samia Cheriet, Anthony Ciabarra, Joseph Classen, Juliana Coleman, Robert Coleman, 42 Yaroslau Compta, Anne-Gaëlle Corbillé, Jean-Christophe Corvol, Mariana Cosgaya, Nabila 43 Dahodwala, Philippe Damier, Elodie David, Thomas Davis, Marissa Dean, Berengere Debilly, Janell 44 DeGiorgio, Andres Deik, Laure Delaby, Marie-Helene Delfini, Pascal Derkinderen, Philipp Derost, 45 Maria de Toledo, Lisa Deuel, Ann Marie Diaz-Hernandez, Cameron Dietiker, Karina Dimenshteyn, 46 Julio Dotor, Franck Durif, Jens Ebentheuer, Karla Maria Eggert, Sara Eichau Madueño, Claudia 47 Eickhoff, Aaron Ellenbogen, Philipp Ellmerer, Ines Esparragosa Vazguez, Alexandre Eusebio. 48 Siobhan Ewert, John Fang, Danielle Feigenbaum, Frederique Fluchere, Alexandra Foubert-Samier, 49 Marie Fournier, Anne Fradet, Valerie Fraix, Samuel Frank, Franca Fries, Monique Galitzky, Marisol 50 Gallardó Pérez, Jose Manuel García Moreno, Carmen Gasca, Thomas Gasser, Joyce Gibbons, 51 Caroline Giordana, Alicia Gonzalez Martinez, Ira Goodman, Arantza Gorospe, Marie Goubeaud, 52 David Grabli, Mangone Graziella, Stephan Grimaldi, Jeffrey Gross, Raquel Guimaraes-Costa, 53 Andreas Hartmann, Christian Hartmann, Travis Hassell, Robert Hauser, Antonio Hernandez, Jorge 54 Hernandez-Vara, Guenter Hoeglinger, Christian Homedes, Andrea Horta-Barba, Jean-Luc Houeto, 55 Julius Huebl, Jennifer Hui, Stuart Isaacson, Joseph Jankovic, Annette Janzen, Junior Jauregui, 56 Jocelyne Jiao, Maria Jose Marti Domenech, Xavier Joseph, Srinath Kadimi, Pat Kaminski, Silja 57 Kannenberg, Jan Kassubek, Maya Katz, Kevin Klos, Shannon Klos, Christopher Kobet, Jennifer 58 Koebert, Patricia Krause, Andrea Kuehn, Jaime Kulisevsky Bojarsky, Rajeev Kumar, Martin Kunz, Lille Kurvits, Kimberly Kwei, Simon Laganiere, Brice Laurens, Johannes Levin, Oren Levy, Peter 59 60 LeWitt, Gurutz Linazasoro Cristóbal, Irene Litvan, Karlo Lizarraga, Katherine Longardner, Rocio 61 Lopez, Lydia Lopez Manzanares, Sara Lucas del Pozo, Maria Rosario Luquin Puido, Nijee Luthra, 62 Kelly Lyons, Sylvia Maass, Gerrit Machetanz, Yolanda Macias, David Maltete, Jorge Uriel Manez 63 Miro, Louise-Laure Mariani, Juan Marin, Kathrin Marini, Ana Marques, Gloria Marti, Maria Jose Marti 64 Domenech, Saul Martinez, Wassilios Meissner, Sara Meoni, Brit Mollenhauer, Dunia Mon Martinez, 65 Johnson Moon, Elena Moro, Peter Morrison, Christoph Muehlberg, Manpreet Multani, Christine 66 Murphy, Anthony Nicholas, Rajesh Pahwa, Antonio Palasi, Heidi Pape, Neepa Patel, Prity Patel, 67 Marina Peball, Elizabeth Peckham, Terry Peery, Rafael Perez, Jesus Perez, Alisa Petit, Elmar 68 Pinkhardt, Werner Poewe, Elsa Pomies, Cecile Preterre, Joseph Quinn, Olivier Rascol, Philippe 69 Remy, Irene Richard, Benjamin Roeben, Emily Ruether, Jost-Julian Rumpf, David Russell, Hayet 70 Salhi, Daniela Samaniego-Toro, Alexandra Samier-Foubert, Antonio Sanchez, Emmanuelle Schmitt, 71 Alfons Schnitzler, Oliver Schorr, Julie Schwartzbard, Kerstin Schweyer, Klaus Seppi, Victoria Sergo, 72 Holly Shill, Andrew Siderowf, Tanya Simuni, Umberto Spampinato, Ashok Sriram, Natividad Stover, 73 Caroline Tanner, Arjun Tarakad, Carolyn Taylor, Claire Thalamus, Thomas Toothaker, Nadege Van 74 Blercom, Nora Vanegas-Arrogave, Lydia Vela, Sylvian Vergnet, Tiphaine Vidal, Jonathan Voeglein, 75 Ryan Walsh, Cheryl Waters, Mirko Wegscheider, Endy Weidinger, Caroline Weill, Gregor Wenzel, 76 Tatiana Witjas, Isabel Wurster, Brenton Wright, Milan Zimmermann, Rafael Zuzuarregui.

Prasinezumab Study Group: Markus Abt, Atieh Bamdadian, Teresa Barata, Nicholas Barbet, Sara Belli, Frank Boess, Azad Bonni, Edilio Borroni, Anne Boulay, Markus Britschgi, Jerome Chague, Valerie Cosson, Christian Czech, Dennis Deptula, Cheikh Diack, Rachelle Doody, Juergen Dukart, Giulia D'Urso, Sebastian Dziadek, Hannah Eddleston, Chris Edgar, Laurent Essioux, Morgan Farell, Rebecca Finch, Paulo Fontoura, Waltraud Gruenbauer, Andrea Hahn, Stefan Holiga, Michael Honer, Shirin Jadidi, Kelly Johnson-Wood, Markus Keller, Timothy Kilchenmann, Martin Koller, Thomas Kremer, Thomas Kustermann, Claire Landsdall, Michael Lindemann, Florian Lipsmeier, Cecile Luzy, Marianne Manchester, Maddalena Marchesi, Ferenc Martenyi, Meret Martin-Facklam, Katerina Mironova, Annabelle Monnet, Emma Moore, Daniel K Ness, Markus Niggli, Tania Nikolcheva, Susanne Ostrowitzki, Gennaro Pagano, Benedicte Passmard, Agnes Poirier, Anke Post, Megana Prasad, Nathalie Pross, Tiffany Quock, Benedicte Ricci, Ellen Rose, Christoph Sarry, Christine Schubert, Dennis Selkoe, Jeff Sevigny, Kaycee Sink, Hannah Staunton, Tim Steven, Alexander Strasak, Hanno Svoboda, Kirsten Taylor, Radhika Tripuraneni, Dylan Trundell, Daniel Umbricht, Lynne Verselis, Annamarie Vogt, Ekaterina Volkova-Volkmar, Cornelia Weber, Silke Weber, Wagner Zago.

Target journal: Frontiers in Neurology (MedRxiv)

92 Abstract (350/350 words, excluding subheadings)

Background

- 94 Currently available treatments for Parkinson's disease (PD) do not slow clinical progression
- 95 nor target alpha-synuclein, the main pathology associated with the disease.

96 **Objective**

- 97 The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized
- 98 monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD.
- 99 The study rationale, design, and baseline characteristics of enrolled subjects are presented
- 100 here.

101

114

93

Methods

- The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled
- treatment study. Individuals with early PD, recruited across the US and Europe, received
- monthly intravenous doses of prasinezumab (1500 mg or 4500 mg) or placebo for a 52-week
- period (Part 1), followed by a 52-week extension (Part 2) in which all participants received
- active treatment. Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage
- 107 I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD
- 108 (e.g. resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment
- naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design
- assumptions for sample size and study duration were built using a patient cohort from the
- Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are
- compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts
- and between the PASADENA and PPMI populations.

115 Results

- Of the 443 patients screened, 316 were enrolled into the PASADENA study between June
- 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. The
- mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II.
- 119 Baseline motor and non-motor symptoms (assessed using Movement Disorder Society –
- 120 Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between
- the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS Total
- score [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall
- 123 PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) also showed
- a similar severity in MDS-UPDRS scores (e.g. MDS-UPDRS Total score [SD]; 31.41 [12.78],
- 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve).

126 Conclusions

- The PASADENA study population is suitable to investigate the potential of prasinezumab to
- slow disease progression in individuals with early PD.
- 129 Trial Registration: NCT03100149
- 130 Total word count: 6086/12000
- 131 4 figures and 1 table

Target journal: Frontiers in Neurology (MedRxiv)

Introduction

There is a high medical need to develop long-lasting therapies that can affect the underlying cause of Parkinson's disease (PD) and, therefore, slow disease progression (1-3). Currently available treatments have powerful symptomatic effects, particularly on motor symptoms, but they do not address the pathological processes underlying the disease and do not prevent or slow clinical decline (2, 3). With the progressive loss of dopaminergic and non-dopaminergic neurons and synapses, available therapies gradually become less effective at controlling PD motor symptoms (4-6). Individuals with PD will invariably develop motor complications and lose their autonomy, adversely affecting their quality of life and placing a significant burden on caregivers, family members and healthcare systems (7-9). Despite the high prevalence and impact of non-motor symptoms on the quality of life of individuals with PD, treatment options for these symptoms are limited (10). A therapy that targets the underlying cause of the disease has the potential to slow motor progression as well as address non-motor symptoms (11, 12).

Postmortem findings suggest that the loss of dopaminergic neurons is accompanied spatially and temporally by the progressive development of intraneuronal Lewy pathology, which is a neuropathological hallmark of PD in distinct brain regions (13-16). Lewy pathology is abnormally enriched in alpha-synuclein, a protein with key functions in neurons (17). Although the etiology of PD is yet to be elicited, the spatio-temporal association between Lewy pathology and neurodegeneration, together with evidence from *in vitro* and *in vivo* models, suggests that pathologically aggregated forms of alpha-synuclein may contribute to axonal and neuronal damage, formation of Lewy pathology and consequent neuronal loss and disease progression (17-21).

Preclinical findings in cellular and animal models also support the hypothesis that certain aggregated forms of alpha-synuclein may be taken up by neurons and may induce the formation of intracellular alpha-synuclein inclusions in PD (19, 22-24). The appearance of intraneuronal inclusions throughout the central and peripheral nervous systems may arise upon propagation of Lewy pathology from neuron to neuron in a concerted manner by extracellular transfer of aggregated alpha-synuclein (20, 25-27).

Clinical evidence also supports the hypothesis that alpha-synuclein is a key driver in the etiology of PD. For instance, both missense mutations (28) and increased production of alpha-synuclein due to duplication or triplication of the synuclein gene (*SNCA*) (29-31) cause early-onset autosomal dominant PD, with virtually 100% penetrance (32). Although the exact patho-physiological mechanism in these genetic causes remains unclear, aggregation of alpha-synuclein due to missense mutation or overexpression is supposed to drive disease onset and progression (33). Direct transfer of aggregated alpha-synuclein from neuron to neuron has not been directly observed in humans. However, embryonic dopaminergic neurons transplanted into the striatum of individuals with PD harbored inclusions reminiscent of Lewy pathology approximately a decade after initial grafting (34, 35) which, together with replicated observations in animal models (22, 23), suggests the possibility of intercellular propagation of Lewy pathology. In support of a caudo-rostral propagation of Lewy pathology, molecular imaging studies demonstrate damage or dysfunction of noradrenergic and serotonergic pathways prior to the dopaminergic pathways in prodromal idiopathic and *SNCA* genetic PD (36, 37).

The growing understanding of the role of alpha-synuclein in the development of Lewy pathology and the pathogenesis of PD support the rationale that targeting alpha-synuclein may have therapeutic potential (38). Preclinical *in vivo* models of alpha-synucleinopathy, such as transgenic mice overexpressing wild-type human alpha-synuclein or that develop pathology upon intracerebral injection of aggregated recombinant alpha-synuclein, are valuable when studying drug mechanisms targeting alpha-synuclein. These models may

help identify the downstream mode of action of therapeutic compounds. Indeed, neuropathological and behavioral deterioration in various mouse models of alpha-synuclein pathology was shown to be ameliorated by treatment with monoclonal antibodies binding to aggregated alpha-synuclein (12, 39-43).

Prasinezumab (previously known as RO7046015/PRX002) is an investigational, humanized monoclonal immunoglobulin G1 antibody directed against an epitope in the carboxyl terminus of human alpha-synuclein (11, 39, 40, 44). It binds to human aggregated alpha-synuclein with a high affinity and avidity (11, 39, 40). Preclinical pharmacologic studies to evaluate efficacy and potency of the murine form of prasinezumab (9E4) were performed in two transgenic mouse lines featuring alpha-synuclein aggregation disorders: Line D and Line 61 mice. The mice were treated with weekly intraperitoneal administration of murine version 9E4 over 5–6 months and showed reduced neuronal and synaptic loss and a reduction in intraneuronal build-up of alpha-synuclein pathology (measured as alpha-synuclein inclusions in cortical and subcortical regions), reduction of gliosis, and an improvement in both cognitive and motor behaviors (12, 39-41).

Although blockade of cell-to-cell transmission of alpha-synuclein by extracellular neutralization of pathogenic species has been proposed as the main mechanism of action of prasinezumab, evidence also supports potential clearance of alpha-synuclein species *via* the lysosomal pathway (12). Together, these preclinical data support the therapeutic potential of prasinezumab in slowing the progression of PD.

In a Phase I single-ascending-dose study in healthy volunteers and a Phase I multiple-ascending-dose study in individuals with PD, prasinezumab was safe, able to penetrate the blood–brain barrier (measured in the cerebrospinal fluid), and showed robust peripheral binding to alpha-synuclein (11, 44). Peripheral binding, measured as the lowering of circulating, free (unbound) serum alpha-synuclein, occurred within 1 hour of administration of prasinezumab and was maintained for longer durations with higher doses of prasinezumab (11). Results also demonstrated a dose-dependent increase of prasinezumab in cerebrospinal fluid concentration, which was approximately 0.3% relative to serum across all dose groups (11). Prasinezumab has a high binding affinity/avidity to aggregated alphasynuclein vs. monomeric alpha-synuclein and, together with the observed cerebrospinal fluid concentrations achieved, it is predicted that >90% of aggregated alpha-synuclein will be engaged in the brain of individuals with PD at doses ≥1500 mg (11). The 1500 mg and 4500 mg doses were selected as both were expected to saturate the target in a Phase II study in individuals with early PD.

Here we report the study rationale, design, and baseline patient characteristics of PASADENA, a Phase II clinical trial testing efficacy and safety of prasinezumab in individuals with early PD. The study design and assumptions for sample size and study duration were built, in part, using a patient cohort from the Parkinson's Progression Markers Initiative (PPMI) study group. The PPMI is a landmark, global, observational clinical study of individuals with PD designed to comprehensively evaluate cohorts of significant interest using advanced imaging, biological sampling and clinical and behavioral assessments to identify biomarkers of PD progression (45). We compared the baseline characteristics of the treatment-naïve and the monoamine oxidase B (MAO-B) inhibitor-treated cohorts of the PASADENA population. We also compared the baseline characteristics of the total PASADENA population with the characteristics of a subset of individuals with early PD enrolled in the PPMI study, which was selected using similar inclusion criteria to the PASADENA study (46).

Methods

237 Study design

The Phase II study of Anti alpha-Synuclein AntiboDy in Early ParkiNson's diseAse (PASADENA) to evaluate the safety and efficacy of prasinezumab (NCT03100149) is an multicenter, randomized, double-blind, placebo-controlled study across approximately 60 sites in the United States, France, Austria, Germany and Spain. The study was designed to evaluate the efficacy and safety of intravenous prasinezumab (received every 4 weeks) in participants with early-stage PD (Hoehn and Yahr [H&Y] Stages I–II, time since diagnosis ≤2 years).

The study consists of two parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1), followed by a 52-week extension period during which all participants received active treatment but remained blinded to original dose allocation (Part 2) (**Figure 1**). A 12-week safety follow-up was mandatory for all participants, regardless of whether cessation of treatment occurred after Part 1 or Part 2.

In Part 1, participants were randomized with a 1:1:1 allocation ratio to either placebo, a high dose (4500 mg for body weight ≥65 kg; 3500 mg for body weight <65 kg) or a low dose (1500 mg for all body weights) of prasinezumab. Body weight has an effect on clearance (and volume of distribution) such that exposure increases in patients with lower body weight. Therefore, the use of an approximately 25% lower dose in participants with lower body weight (<65 kg) is implemented at high doses where there is an increased risk for infusion-related reactions. To reduce the risk of infusion-related reactions, participants in the high-dose group received a 2000 mg intravenous infusion on Day 1 followed by an up-titration to the full dose on Day 28 which they then received every 4 weeks. In addition, the first three study treatment infusions (irrespective of treatment allocation) were prolonged to 2 hours and were preceded by pre-medication with non-sedating antihistamine and acetaminophen (11). Randomization was stratified by sex, age group (<60 years vs. ≥60 years) and use of MAO-B inhibitor at baseline (yes vs. no).

Participants from Part 1 were eligible to continue to Part 2 provided dopamine transporter single-photon emission computerized tomography (DaT-SPECT) and magnetic resonance imaging (MRI) scans had been completed at screening and Week 52, and participants had received at least 10 doses of study treatment (placebo or prasinezumab) during Part 1.

In Part 2, participants randomized to treatment with prasinezumab in Part 1 remained on the same dose for the duration of Part 2. Those participants initially randomized to placebo were re-randomized to either 1500 mg or 4500 mg prasinezumab using a 1:1 allocation ratio. Randomization was stratified by dopaminergic therapy since start of study (yes vs. no), sex, age group at start of study (<60 years vs. ≥60 years) and use of MAO-B inhibitor at baseline (yes vs. no).

If symptomatic treatment was initiated during Part 1, investigators were required to record the reason(s) and the type and dose of symptomatic PD treatment prescribed. Participants who initiated symptomatic PD treatment could then continue in the study, as per their regular scheduled study visits. For participants who started dopaminergic treatment (levodopa or dopamine agonist), the Movement Disorder Society – Unified PD Rating Scale (MDS-UPDRS) including Part IV (motor assessment while on dopaminergic treatment) and digital biomarker in-clinic assessments at subsequent visits were performed in an "Off" state, i.e. patients had not received levodopa since the previous evening (>8 hours prior). The MDS-UPDRS Part III (motor assessment) was repeated at least 1 hour after receiving levodopa in the clinic (while patients are in an "On" state), along with digital biomarker in-clinic assessments.

Target journal: Frontiers in Neurology (MedRxiv)

Study population

289 290 291

292

293 294

295 296

297 298

299 300

301 302

303 304

305

306 307

308 309

310 311 312

316

322

334

The inclusion and exclusion criteria were developed to select an early PD population with a measurable and precitable rate of progression over a 1-year period.

Key inclusion criteria included: idiopathic PD with bradykinesia and one of the other cardinal signs of PD (resting tremor, rigidity) and no other known or suspected cause of PD; aged 40–80 years; a DaT-SPECT consistent with PD; body weight range of ≥45 kg to ≤110 kg and a body mass index of 18 to 34 kg/m²; and either treatment naïve or on a stable dose of a MAO-B inhibitor for at least 90 days.

Key exclusion criteria included: medical history indicating a Parkinson syndrome other than idiopathic PD; known carriers of certain familial PD genes (Parkin, PINK1, DJ1); Mini Mental State Examination (MMSE) ≤25; use of any of the following: catechol-O-methyl transferase inhibitors (entacapone, tolcapone), amantadine or anticholinergics, or dopaminergic medication (levodopa and both ergot and non-ergot [pramipexole, ropinirole, rotigotine] dopamine agonists) for more than a total of 60 days or within 60 days of baseline and prior participation in any prasinezumab study.

A full list of inclusion and exclusion criteria can be found in Table 1 and Table 2 in the Supplementary Materials.

Objectives and endpoints

- Clinical assessments performed at baseline and at different study visits are summarized in 313
- 314 Figure 2 and Figure 3. A full list of endpoints is available online in the PASADENA study
- protocol (NCT03100149) (47). 315

317 Primary endpoint

- 318 The primary objective of the study was to assess the efficacy of prasinezumab 1500 mg and
- 4500 mg vs. placebo at Week 52 in enrolled participants. The primary endpoint was the 319
- change from baseline at Week 52 in MDS-UPDRS Total score (sum of Parts I, II and III) vs. 320
- placebo. 321

Secondary endpoints 323

- 324 The effects of prasinezumab 1500 mg and 4500 mg vs. placebo at Week 52 on MDS-
- UPDRS Part IA, Part IB, Part I total, Part II total, Part III total and Part III subscores 325
- 326 (bradykinesia, rigidity, resting tremor and axial symptoms) were included as secondary
- 327 endpoints. Part I assessed non-motor experiences of daily living, with Part IA focused on
- complex behaviors (cognitive impairment, hallucinations and psychosis, etc.) and Part IB 328
- 329 focused on non-motor experiences (sleep and urinary problems, constipation, pain, etc.).
- Part II assessed motor experiences of daily living (eating, dressing, handwriting, getting out 330
- of bed, etc.) and Part III assessed motor signs of PD (speech, finger tapping, bradykinesia, 331
- 332 gait and freezing, etc.) (48). Part IA and Part III were administered by the study investigator.
- 333 and Part IB and Part II were completed by the participant.
- 335 Other secondary endpoints included; Montreal Cognition Assessment (MoCA) Total score;
- 336 Clinical Global Impression of Improvement (CGI-I): Patient Global Impression of Change
- (PGI-C); DaT-SPECT in the ipsilateral (to the clinically dominant side) putamen; Schwab and 337
- England Activity of Daily Living (SE-ADL) score; time to worsening in motor or non-motor 338
- 339 symptoms (increase of ≥3 points in MDS-UPDRS Part I or MDS-UPDRS Part II); time to start
- 340 of dopaminergic PD treatment (levodopa or dopamine agonists); and safety, tolerability,

Target journal: Frontiers in Neurology (MedRxiv)

immunogenicity, and pharmacokinetics (PK) of prasinezumab. Safety and tolerability were assessed for up to 104 weeks, with or without dopaminergic treatment. PK of prasinezumab was assessed using population PK modeling.

Exploratory endpoints

341

342 343

344

345

346 347

348

349 350

351

352 353

354

355

356 357 358

359

360

361

362

363 364

365

366 367

368

369

370 371

372

373 374

375

376

377 378

379

380

381

382 383

384

385

Exploratory endpoints of this study included: MDS-UPDRS Part III subscores determined by independent central raters (using video recordings to address consistency and accuracy in the trained site raters), imaging analysis of striatum, caudate and putamen (average, ipsilateral and contralateral) for DaT-SPECT binding ratio values, and the change from baseline on a sensor-based measure derived from Roche PD Mobile Application v2 digital biomarkers (49) (smartphone and wrist-worn wearable) assessments (see Figure 4 for an overview of the remote monitoring tests). The analyses of primary and secondary endpoints were also repeated, with the results for the two prasinezumab 1500 mg and 4500 mg pooled doses vs. placebo, as a pre-specified exploratory analysis.

A full list of endpoints exploratory endpoints is included in Supplementary Table 3.

PASADENA Digital Motor Score

Summary scores of sensor data from digital health technology tools should be developed independent of existing clinical data to ensure that the digital score does not inherit the shortcomings of the clinical measure (e.g. restriction of range, reduced resolution of scale). However, this requires independent longitudinal sensor datasets to build and validate such a digital score (49). Since such data are not yet available, a provisional single summary sensor-based measure, the 'PASADENA Digital Motor Score', reflecting global motor function was developed. Data from a PASADENA-like PPMI cohort were used to inform sensor feature selection for the PASADENA Digital Motor Score, as follows: MDS-UPDRS Part II and III item-level scores which significantly declined in Year 1 of PPMI were identified (n=21; whereby one item (posture) was not tested with the digital biomarker; final set of MDS-UPDRS items = 20). A blinded subset of PASADENA data (n=157) was used to map sensor feature data (aggregated over 2-week periods) onto each MDS-UPDRS item with the blinded PASADENA population. The set of sensor features was used to predict the sum of the 20 identified MDS-UPDRS items. PASADENA Digital Motor Scores were generated for every two weeks of the study and submitted to linear random coefficient (i.e. slope) models testing for differences in slopes between censored patients in each treatment group over the 26 two-week periods of the PASADENA study.

A second set of exploratory digital biomarker analyses comprised 17 individual pre-specified sensor features, which were selected based on a previous communication that reported cross-sectional correlations between sensor features and MDS-UPDRS scores (50) and available literature. These individual sensor features were also analyzed with linear random coefficient models testing for differences in slopes across treatment groups if the model's residuals were normally distributed; if the residuals were not normally distributed, mixed effects models with repeated measures were applied.

Standard protocol approvals, registrations, and patient consents

This study was conducted in full conformance with the International Conference on 386 387 Harmonization E6 guideline for Good Clinical Practice and the principles of the Declaration 388 of Helsinki, or the laws and regulations of the country in which the research was conducted, 389 whichever afforded the greater protection to the individual. The study protocol, Informed

390 Consent Forms, and any information given to the participant, were approved by the

391 Institutional Review Board or Ethics Committee (NCT03100149).

392 Sample size justification

A sample size of approximately 100 randomized participants per group (300 participants in total for the three groups) was estimated, which allowed for a power of approximately 80% at two-sided α-level of 20% to detect a three-point difference in MDS-UPDRS Total score between groups from baseline at Week 52. The power calculation was based on simulations of the mixed-effect model for repeated measures (MMRM) analysis planned for the primary efficacy variable. Assessments performed while on any symptomatic therapy started after randomization were not included in the analysis of the primary endpoint.

The assumptions on progression, variability, dropout rate and likelihood to start symptomatic therapy within the first 52 weeks of treatment, with or without a MAO-B inhibitor as background therapy, were derived from analyses based on the PPMI database and various sources of information from the literature (46, 51). The percentage of patients defined as non-evaluable at Week 52 was predicted to be 25% in the placebo group and 20% in the treatment groups. This estimate included non-evaluable data from patients who prematurely dropped out and/or started symptomatic therapy after randomization.

The sample size of 100 patients per arm also provided 76% power (α = 20%, two sided) to reject the null hypothesis, assuming a 37.5% reduction for the key secondary endpoint, the DaT-SPECT signal loss at Week 52 and the pairwise comparison of each active dose arm with placebo (46, 51).

Covariate adjustment

393

394 395

396

397

398 399

400 401

402 403

404

405

406

407

408 409

410

411

412413

414

429

430

431

432 433

434

435 436 437

438

439 440

441 442

- Analyses of efficacy endpoints (primary, secondary, and exploratory) included the following
- covariates in the model: background therapy at baseline (MAO-B inhibitor treatment [yes vs.
- no]), age group (<60 years vs. ≥60 years), sex (male vs. female), DaT-SPECT binding ratio
- in the contralateral (to the clinically most affected side) putamen at baseline, and treatment
- group (4500 mg prasinezumab, 1500 mg prasinezumab or placebo). For each continuous
- endpoint the baseline of the endpoint variable was included in the model.
- 421 Statistical analyses of primary efficacy endpoint
- 422 Change in MDS-UPDRS Total score from baseline vs. placebo was analyzed using an
- 423 MMRM, with covariates described in the *Covariate adjustment* section as fixed effects. The
- 424 model also included baseline MDS-UPDRS Total score, week of treatment (as a categorical
- 425 factor), a treatment-by-week interaction term and an interaction term between baseline
- 426 MDS-UPDRS by week. An unstructured variance-covariance matrix was used to model the
- random error. The model tested the null hypothesis of no treatment difference at a two-sided α-level of 20% for the following comparisons:
 - 4500 mg or 3500 mg (high dose) prasinezumab vs. placebo
 - 1500 mg (low dose) prasinezumab vs. placebo.

All the assessments flagged on and after the "first symptomatic PD treatment date" (either initiation of symptomatic PD treatment or a change to MAO-B inhibitor dose) were not included in the analysis. The primary endpoint of MDS-UPDRS Total score (sum of Parts I, II, and III) was re-analyzed with data from the two treatment arms pooled, and compared with placebo as an exploratory endpoint.

Statistical analyses of secondary and exploratory efficacy endpoints

For the endpoints utilizing MDS-UPDRS Part IA, Part IB, Part I total, Part II total, Part III total, Part III subscores, CGI-I, and PGI-C, the information collected after symptomatic PD treatment was handled as for the primary analysis. The analysis of all other endpoints included all the data available regardless of start of symptomatic PD treatment.

An analysis of covariance (ANCOVA) was used to analyze the change from baseline at Week 52 in MoCA Total score and SE-ADL score with covariates described in the *Covariate adjustment* section. The change (between baseline and Week 52) in DaT-SPECT striatal binding ratio in the ipsilateral (to the clinically most affected side) putamen, was analyzed using ANCOVA. Arterial spin labeling (ASL) MRI was performed at sites with the technical capability. Effects are tested for in pre-specified regions of interest; striatum, caudate, and putamen (ipsilateral, contralateral, and average were assessed for each region). Betweengroup changes in ASL MRI over 1 year in regions of interest were also tested using ANCOVAs.

The CGI-I was intended as a measure of change in health status from baseline CGI - Severity of illness (CGI-S). For the CGI-I, patients were divided into one of two groups:

- 'Responders': Score of 1–4 (i.e. rated as "no change", "minimally improved", "much improved" or "very much improved").
- 'Progressors': Score of 5–7 (i.e. rated as "minimally worse", "much worse" or "very much worse").

The proportion of patients rated by CGI-I grouping at Week 24 and Week 52 was analyzed using a logistic regression model. The estimated odds ratio for 'responders' and 'progressors' at Week 24 and Week 52 for treated patients compared with placebo were calculated with 80% confidence interval. Analysis of the PGI-C followed the same methodology outlined for the CGI-I above.

Time to worsening of motor or non-motor symptoms (of ≥3-point change from baseline in MDS-UPDRS Part I or Part II) and time to start of dopaminergic (levodopa or dopamine agonist) treatment were plotted using a Kaplan-Meier survival plot and analyzed using a Cox proportional hazards model to obtain a treatment difference between each of the prasinezumab dose levels against placebo. A 3-point minimum change in MDS-UPDRS Part II was chosen as this has been previously identified as the smallest change of score that is clinically meaningful to patients (52).

Subgroup analyses

Subgroups with ≥20% of patients from the modified intent-to-treat population at baseline were analyzed. The model used for the primary endpoint was run in each subgroup, excluding the subgroup being analyzed if that was a covariate (e.g. MAO-B inhibitors at baseline [yes vs. no]).

The subgroup analyses were performed in the primary endpoint and the following secondary/exploratory endpoints:

- MDS-UPDRS Part I
- MDS-UPDRS Part II
- MDS-UPDRS Part III Total score and subscores
- MDS-UPDRS sums of Part II and III
- DaT-SPECT striatal binding ratio in the ipsilateral (to the clinically most affected side) putamen
- PASADENA Digital Motor Score
- MoCA score
- Composite time to event.

Subgroups included in analyses were:

- MAO-B inhibitors at baseline (yes vs. no)
- H&Y Stage at baseline (I vs. II)
- Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ) at baseline (RBDSQ ≥5 vs. <5)
- Data-driven subphenotypes (Diffuse malignant vs. mild motor predominant vs. intermediate) at baseline

- Alpha-synuclein skin (positive vs. negative) (staining by immunohistochemistry on skin biopsy sections at baseline)
- DaT-SPECT striatal binding ratio in the ipsilateral (to the clinically most affected side) (very abnormal vs. abnormal) putamen.

For the derivations of the data-driven subphenotypes, scales were classified into: motor scales (MDS-UPDRS Part II and MDS-UPDRS-Part III) and non-motor scales (Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction [SCOPA-AUT], RDBSQ and MoCA). After each one of the scales had been divided into percentiles, the data-driven subphenotypes were defined as follows:

- Diffuse malignant: Score on motor scales being greater than the 75th percentile; and at least one score on a non-motor scale greater than the 75th percentile; or all three non-motor scores greater than the 75th percentile
- Mild motor predominant. Motor and all non-motor scores less than the 75th percentile
- Intermediate: All those individuals not meeting criteria for other subtypes.

Inclusion criteria for the PPMI cohort

496

497

498 499

500

501

502

503504

505

506

507

508

509 510

511

512

513

514

515516

517

518519

520 521

522523

524 525

526 527

528 529

530

531532

533

534535

536

537

The design of this study and the assumptions for progression, variability, dropout rate and likelihood to start symptomatic therapy within the first 52 weeks of treatment, with or without a MAO-B inhibitor, were derived from analyses of data collected in the PPMI observational clinical study. Details regarding the PPMI study have been previously published and are available at ppmi-info.org (53, 54). Patients from the PPMI population were selected for comparison with the PASADENA cohort using the following criteria, which align with the PASADENA study criteria: to have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia) and confirmation from imaging core that DaT-SPECT screening was consistent with dopamine transporter deficit. Data were downloaded in May 2020 and, from the total 423 individuals in the PPMI population, a cohort of 336 participants were selected based on the above criteria. No individuals in the PPMI cohort received MAO-B inhibitors at baseline.

Statistical comparisons between PASADENA and PPMI cohorts

The standardized mean difference (SMD) in prognostic scores was used to assess differences between baseline data for the PASADENA and PPMI cohorts, and for the PASADENA MAO-B inhibitor-treated vs. treatment-naïve patient groups. The SMD was calculated as the absolute value in the difference in means of a covariate across the treatment groups, divided by the pooled SD. SMDs larger than 0.25 indicate that the groups were too different from one another for a reliable comparison of change from baseline in that variable (55). Overall, 20 covariates were selected for the analysis, including demographic, imaging and clinical assessment (MDS-UPDRS Part I, II and III) data.

Results of baseline data analysis

Baseline PASADENA demographics

- A total of 443 patients were screened between June 2017 and November 2018 at 60 sites.
- Overall, 127 patients failed screening due to not meeting certain inclusion and exclusion
- 540 criteria, such as brain DaT-SPECT screening consistent with PD, concomitant disease or
- condition within 6 months of screening and MMSE ≤25. Overall, 316 patients were enrolled
- at 57 centers across the following five countries: United States (160 patients [50.6%]), Spain
- 543 (50 patients [15.8%]), France (65 patients [20.6%]), Germany (35 patients [11.1%]), and
- Austria (6 patients [1.9%]). Of those patients enrolled into the PASADENA study, 115 (36%)
- had received MAO-B inhibitor treatment at enrollment and 201 (64%) were treatment naïve.
- 546 The mean (SD) age of PASADENA patients was 59.9 (9.10) years and the population
- included 213 (67.4%) men and 103 (32.6%) women, with a mean time from diagnosis of

- 10.11 (6.50) years and 238 (75.3%) individuals being H&Y Stage II. The mean (SD) MDS-
- 549 UPDRS Total score at baseline was 31.41 (12.78) and the mean total scores for the
- individual parts were: Part I, 4.61 (3.83); Part II, 5.33 (4.04) and Part III, 21.47 (9.00). The
- mean baseline DaT-SPECT striatal binding ratios for the PASADENA population were 0.80
- 552 (0.25) for the contralateral putamen and 1.06 (0.32) for the ipsilateral putamen.
- 553 MAO-B inhibitor treated vs. treatment-naïve patients in the PASADENA population
- Within the PASADENA study population, patients treated with MAO-B inhibitors at baseline
- were on average younger (58.2 [9.00] years vs. 60.8 [9.00] years, respectively; SMD:
- 556 –0.290) and had a longer time from diagnosis (11.96 [6.10] months vs. 9.06 [6.50] months,
- respectively; SMD: 0.461) vs. the treatment-naïve group. MAO-B inhibitor-treated patients
- also had a higher MoCA score vs. the treatment-naïve group (28.27 [1.96] vs. 27.65 [2.04],
- respectively; SMD: 0.309). All other baseline characteristics were balanced between patients
- who received a MAO-B inhibitor (n=115) and those who were treatment naïve (n=201)
- 561 (Table 1 and Supplementary Figure 1).
- 562 PASADENA population vs. PPMI cohort, selected using PASADENA eligibility criteria
- When comparing the PASADENA population baseline characteristics with those of the PPMI
- cohort, MDS-UPDRS mean scores were lower for the PASADENA population for Part I (4.61
- 565 [3.83] vs. 5.60 [3.93], respectively; SMD: 0.255) and Part IB (3.45 [2.78] vs. 4.33 [3.10],
- respectively; SMD: 0.297) compared with the PPMI cohort. The PASADENA population had
- a longer average time from diagnosis (10.11 [6.50] years vs. 6.44 [6.31] years, respectively;
- 568 SMD: -0.573) compared with the PPMI cohort. DaT-SPECT striatal binding ratios for the
- PASADENA population for the contralateral putamen (0.80 [0.25] vs. 0.68 [0.27],
- respectively; SMD: -0.445) and ipsilateral putamen (1.06 [0.32] vs. 0.96 [0.39], respectively;
- 571 SMD: -0.285) to the clinically most affected side were both higher compared with the PPMI
- 572 cohort. On average, PASADENA patients scored higher in MoCA (27.87 [2.03] vs. 27.24
- 573 [2.29], respectively; SMD: –0.291) and lower in SCOPA-AUT (8.05 [5.71] vs. 9.75 [6.23],
- 574 respectively; SMD: 0.284) scores compared with the PPMI cohort. All other baseline
- characteristics were balanced between the PASADENA population and the PPMI cohort
- 576 (Table 1 and Supplementary Figure 2).

Discussion

577

- 578 PASADENA is the first Phase II study to test the efficacy of a monoclonal antibody binding
- aggregated alpha-synuclein to slow disease progression in early PD. The PASADENA study
- enrolled individuals diagnosed with early-stage PD, requiring that they be, inter alia, either
- treatment naïve or on stable treatment with MAO-B inhibitors and have a DaT-SPECT-
- confirmed dopaminergic deficit. In order for this Phase II proof-of-concept study to measure
- the disease-modifying potential of prasinezumab within the study period of 1 year, it was
- essential to define a population with a measurable rate of progression. The progression rate
- may depend on baseline disease severity and other factors (56). Several previous studies
- have reported that the progression rate in individuals with early PD is generally faster shortly
- after diagnosis of PD and before the start of levodopa or dopamine agonist therapy usage
- 588 (46, 57). Individuals at this early stage of disease still have vulnerable dopaminergic neurons
- and protecting them against the development of further alpha-synuclein pathology may
- 590 potentially slow motor disease progression. A 1-year treatment duration, if well powered, is
- expected to be sufficient to demonstrate relevant between-group differences, resulting from
- an effect of treatment on disease progression in individuals with early PD.
- 593 Current treatments for PD, such as levodopa, improve motor symptoms and aim to increase
- 594 dopamine levels, compensating for the dopaminergic cell and synaptic loss (58). It is
- 595 possible that the potential effects of treatment with a disease-modifying therapy on motor
- symptoms in individuals with early PD might be masked by these powerful symptomatic

 therapies (46, 54). People with early PD treated with MAO-B inhibitors have a reduced likelihood of starting levodopa or dopamine agonists therapy compared with placebo, while maintaining a relatively high progression rate (56, 57). Individuals with early PD who were either treatment naïve or treated with a MAO-B inhibitor at baseline were, therefore, included in Part 1 of the PASADENA study. The recruited PASADENA study population was also similar to other early PD therapeutic trial populations (56, 59, 60).

In this study, a comparison of the baseline characteristics of PASADENA study participants showed that those who received treatment with MAO-B inhibitors were younger with a longer time from diagnosis compared with the treatment-naïve group; however, the two groups had similar overall symptom severity at baseline. This observed similarity may be due to improvement in MDS-UPDRS scores as a result of MAO-B inhibitor treatment, which provides symptomatic relief to individuals with early PD by prolonging the action of dopamine in the brain (61, 62). The younger age may be due to the fact that individuals with older onset of PD usually receive levodopa rather than MAO-B inhibitors (63).

The design and assumptions of this study were informed from analyses of data collected in the PPMI observational clinical study. Therefore, it was important to compare the baseline characteristics of the PASADENA study population with the PPMI cohort to ensure the assumptions made were also valid for the PASADENA population. The PASADENA population and PPMI cohort showed different distributions for some demographic measures; for example, more PASADENA participants were in H&Y Stage II (75% vs. 59%) and had on average a 3.7-month-longer time from diagnosis than the PPMI cohort. However, the DaT-SPECT striatal binding ratios for both the ipsilateral and contralateral putamen suggested that the PASADENA population had a slightly less advanced disease in terms of severity and potentially of progression.

Dose selection for the PASADENA trial was based on data from previous studies. In a Phase I multiple-ascending-dose study (NCT02157714), individuals with mild-to-moderate PD who received prasinezumab up to 60 mg/kg intravenously every 4 weeks reported no serious or severe adverse events (11). Rapid-dose and time-dependent mean reductions from baseline vs. placebo in free serum alpha-synuclein levels of up to 97% were reported in trial participants after a single infusion at the highest dose (P=0.002), with similar reductions after two additional infusions. Mean cerebrospinal fluid concentration of prasinezumab also increased with dose, to approximately 0.3% relative to the concentration in serum across all dose cohorts. Currently, assays to quantify engagement of prasinezumab with aggregated forms of alpha-synuclein in vivo are not available. Thus, the dose selection for the Phase II study was primarily based on human serum and cerebrospinal fluid pharmacokinetic data extrapolation, and the relationship of these data with histopathological and functional endpoints. The doses used in the PASADENA trial were selected to fall in the therapeutic exposure range predicted from preclinical efficacy models; the high prasinezumab dose (4500 mg for body weight ≥65kg; 3500 mg for body weight <65kg) was selected to match exposure at the 60 mg/kg dose in the multiple-ascending-dose study, and the 1500 mg prasinezumab dose to vield exposure levels above those effective on alpha-synuclein pathology in the mouse model, with sufficient separation between the two to enable exposure response analyses. Both doses selected were expected to bind >90% of pathological aggregated alpha-synuclein, as well as monomers, in the central nervous system, thus both could show signal of efficacy on disease progression.

The effect of treatment with prasinezumab on clinical progression rate was determined using the MDS-UPDRS and was supported with a panel of exploratory biomarkers assessing the potential effects on PD pathology and progression of neuronal damage. The MDS-UPDRS is comprised of four parts: Part I, Mentation, Behavior, and Mood; Part II, Activities of Daily Living; Part III, Motor Examination; and Part IV, Complications of Therapy (48, 64). Each parkinsonian sign or symptom is rated on a 5-point scale (ranging from 0 to 4), with higher

Target journal: Frontiers in Neurology (MedRxiv)

scores indicating more severe impairment (64). The MDS-UPDRS demonstrates good reliability, validity and sensitivity to change over a range of measures of time from diagnosis and severity (64). Previous studies in individuals with early PD have demonstrated a linear increase in MDS-UPDRS of approximately 6–12 points per year following diagnosis and prior to initiating symptomatic treatment (46, 54, 56, 57). A positive effect on MDS-UPDRS scores may, therefore, indicate a potential effect on global PD progression of prasinezumab. It is important to note that the increase in MDS-UPDRS scores in the treatment-naïve population with early PD is derived from the Part III motor examination scores; this population exhibits decline to a far lesser extent in activities of daily living (MDS-UPDRS Part II) and motor problems in daily life (MDS-UPDRS Part III) (64).

A striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT currently represents the most established imaging marker in PD, reflecting neurodegeneration in key brain regions affected by alpha-synuclein pathology. Regardless of dopaminergic treatment, individuals with early PD show the fastest decrease of DaT-SPECT signal (i.e. loss of dopaminergic terminals) resulting in an inverse exponential decline in striatal DaT-SPECT uptake values (65, 66). Therefore, DaT-SPECT will be used as a secondary outcome measure in the PASADENA study to determine the disease-modifying potential of prasinezumab.

Smartphones and smartwatches are built with high-quality sensors that, together with novel software technologies, enable the remote, non-invasive, frequent and sensitive measurement and analysis of motor and in PD (67-69). Digital monitoring of motor symptoms using smartphones has been previously used in the Phase I study of prasinezumab in individuals with PD (NCT02157714). Study participants completed a daily battery of tests and carried the phone with them throughout the day for passive monitoring. The study revealed high adherence and a strong correlation between smartphone sensor data and clinical measures of motor signs and, notably, the detection of clinical manifestations that were not apparent at site visits (70). A second version of this digital biomarker approach was therefore implemented in the PASADENA study to maximize the probability of detecting a potential therapeutic effect of prasinezumab and potentially provide new insights into the functioning and behavior of individuals with PD.

A definitive diagnosis of PD can only be made *post mortem* as biomarker tools that detect alpha-synuclein in the brain *in vivo* are not currently available (71). However, pathological forms of alpha-synuclein have been detected in peripheral neurons present in skin biopsy samples from individuals with PD; the degree of peripheral nerve pathology detected in samples was found to correlate with disease severity (72, 73). Longitudinal skin biopsy sampling has been implemented in the PASADENA study for the direct and *in vivo* assessment of alpha-synuclein pathology, and its progression in response to treatment with prasinezumab. Clinical data and samples, including skin biopsies, will be collected from DaT-SPECT negative screen failure participants to determine whether the detection of alpha-synuclein skin pathology may be used as a sensitive, specific, and less invasive tool to diagnose PD.

Conclusions

The PASADENA Phase II study was designed to assess the safety and tolerability and clinical effect on disease progression of prasinezumab in patients with early PD. This study will focus on the effect of treatment in early PD, as disease progression is measurable and predictable in this cohort and will not be masked by treatment with dopaminergic therapy. The primary outcome measure will be supported by clinical measures and imaging to investigate the potential physiological impact of treatment. In addition, novel digital biomarkers will be used to assess potentially subtle effects of treatment on motor function in individuals with PD.

Target journal: Frontiers in Neurology (MedRxiv)

Data availability

700

710

- 701 Qualified researchers may request access to individual patient-level data through the clinical
- study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible
- studies are available here (https://vivli.org/members/ourmembers/). For further details on
- Roche's Global Policy on the Sharing of Clinical Information and how to request access to
- 705 related clinical study documents, see here
- 706 (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_tri
- 707 <u>als/our_commitment_to_data_sharing.htm</u>). Data used in the preparation of this article were
- obtained from the Parkinson's Progression Markers Initiative (PPMI) database (ppmi-
- info.org/data). For up-to-date information on the study, visit ppmi-info.org.

Ethics statement

- 711 Participants were identified for potential recruitment using site-specific recruitment plans
- 712 prior to consenting to take part in this study. Recruitment materials for participants had
- 713 received Institutional Review Board or Ethics Committee approval prior to use. The following
- 714 Institutional Review Boards ruled on ethics of the PASADENA study: Ethikkommission der
- 715 Medizinischen Universität Innnsbruck, Innsbruck, Austria; Comité de Protection des
- Personnes (CPP) Ouest IV, Nantes, France; Ethikkommission der Universität Leipzig and
- 717 Geschäftsstelle der Ethikkommission an der medizinischen Fakultät der Universität Leipzig,
- Leipzig, Germany; Ethikkommission der Fakultät für Medizin der Technischen Universität
- 719 München, München, Germany; Ethikkommission der Universität Ulm (Oberer Eselsberg),
- 720 Ulm, Germany; Landesamt für Gesundheit und Soziales Berlin and Geschäftsstelle der
- 721 Ethik-Kommission des Landes Berlin, Berlin, Germany; Ethikkommission des FB Medizin der
- 722 Philipps-Universität Marburg, Marburg, Germany; Ethikkommission an der Medizinischen
- 723 Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen, Tübingen,
- 724 Germany; Ethikkommission an der Med. Fakultät der HHU Düsseldorf, Düsseldorf,
- 725 Germany; Ethikkommission der LÄK Hessen, Frankfurt, Germany; CEIm Hospital
- Universitari Vall d'Hebron, Barcelona, Spain; Copernicus Group Independent Review Board,
- Puyallup, Washington, USA; Western Institutional Review Board, Puyallup, Washington,
- 728 USA; The University of Kansas Medical Center Human Research Protection Program,
- 729 Kansas City, Kansas, USA; Oregon Health & Science University Independent Review Board,
- 730 Portland, Oregon, USA; Northwestern University Institutional Review Board, Chicago,
- 731 Illinois, USA; Spectrum Health Human Research Protection Program, Grand Rapids,
- 732 Michigan, USA; The University of Vermont Committees on Human Subjects, Burlington,
- 733 Vermont, USA; Beth Israel Deaconess Medical Center Committee on Clinical Investigations,
- New Procedures and New Forms of Therapy, Boston, Massachusetts, USA; Vanderbilt
- 735 Human Research Protection Program Health, Boston, Massachusetts, USA; Vanderbilt
- Human Research Protection Program Health, Nashville, Tennessee, USA; University of
- 737 Maryland, Baltimore Institutional Review Board, Baltimore, Maryland, USA; University of
- 738 Southern California Institutional Review Board, Los Angeles, California, USA; Columbia
- University Medical Center Institutional Review Board, New York, New York, USA; University
- of Southern California San Francisco Institutional Review Board, San Francisco, California,
- 741 USA; University of Pennsylvania Institutional Review Board, Philadelphia, Philadelphia,
- 742 USA; HCA HealthOne Institutional Review Board, Denver, Colorado, USA. All Institutional
- Review Boards gave ethical approval of the study.

Funding statement

744

745

- The PASADENA study was funded by F. Hoffmann-La Roche Ltd.
- PPMI, a public-private partnership, is sponsored by the Michael J. Fox Foundation (MJFF)
- for Parkinson's Research and is co-funded by MJFF, AbbVie, Allergan, Amathus
- 749 Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biogen Idec, BioLegend, Bristol-
- 750 Myers Squibb, Calico, Celgene, Denali Therapeutics Inc., 4D Pharma Plc, Eli Lilly and
- 751 Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Genentech Inc, GlaxoSmithKline,
- 752 Golub Capital BDC, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck,

Meso Scale, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Sanofi Genzyme, Servier, Takeda, Teva Pharmaceutical Industries Ltd, UCB, Verily Life Sciences and Voyager Therapeutics. Industry partners contribute to PPMI through financial and inkind donations and have a lead role in providing feedback on study parameters through the Partners Scientific Advisory Board (PSAB). Through close interaction with the study, the PSAB is positioned to inform the selection and review of potential progression markers that could be used in clinical testing.

Acknowledgments


 The authors thank all the subjects who participated in this study. The authors thank Sarah Child of MediTech Media for providing medical writing support and Megan Speakman of MediTech Media for medical editing assistance, which were funded by F. Hoffmann-La Roche, in accordance with Good Publication Practice (GGP3) guidelines (http://www.ismpp.org/gpp3).

Author contributions

GP, FGB, KIT, BM, WP, GGK, WMZ, DKN, SO, KM, MK and JS designed the study. GP, FGB, KIT, BM, WP, AnB, AV, MM, AP, SO and TS were involved in data collection. GP, KIT, BR, JAC, AV and MM analyzed the data. All authors were involved in data interpretation. GP and AzB drafted the work. GP, FGB, KIT, BR, BM, WP, JAC, AP, TN, GGK, WMZ, HS, SO, TS, KM, MK, JS, RD, PF, DU, and AzB critically revised important intellectual content. All authors revised and gave input on the article. GP and AzB provided final approval of the manuscript.

Tables and figures

Figure 1. PASADENA study design schematic



*Low dose = 1,500 mg, †High dose = 4,500 mg for ≥65 kg; 3,500 mg for <65 kg. DaT-SPECT, dopamine transporter imaging with single-photon emission computerized tomography; IV, intravenous; Q4W, every month.

Figure 2. Schedule of activities in PASADENA Part 1

	Screening	Baseline	Week 8	Week 16	Week 24	Week 32	Week 40	Week 48	Week 52
MDS-UPDRS	~	~	~	~	~	~	~	~	~
MoCA	~	~			~				~
					~				~
PGI-C					~				~
SE-ADL		~			~				~
PDQ39 *	~				~			~	
SCOPA-AUT [†]	~			~			~		~
PDSS-2		~			~			~	
① DaT-SPECT	~								~
Digital biomarker‡									
MRI ^s	~								~
Skin biopsy	~								~
Modified H&Y	~		~	~	~	~	~	~	~
Only at screening:	MMSE, RBD	Q. Only at b	aseline: C0	∃I-C.					

*Parkinson's Disease Questionnaire – 39 (PDQ39) is at baseline, Week 20 and Week 48; †SCOPA-AUT (Scales for outcomes in Parkinson's disease autonomic dysfunction) is at baseline, Weeks 16, 28, 40 and 52. †Digital includes PASADENA Digital Motor Score, Patient Global Impression of Severity, Daily diary, Patient Assessment of Constipation Symptoms (PAC-SYM), EuroQol-5D (EQ-5D) and Hospital Anxiety and Depression Scale (HADS). §Magnetic resonance imaging (MRI) includes safety, diffusion tensor imaging (DTI), resting state and arterial spin labeling (ASL).

CGI-I, Clinical Global Impression of Change; CGI-I, Clinical Global Impression of Improvement; DaT-SPECT, dopamine transporter imaging with single-photon emission computerized tomography; H&Y, Hoehn & Yahr; MDS-UPDRS, Movement Disorder Society – Unified Parkinson's Disease Rating Scale; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; PDSS-2, Parkinson's Disease Sleep Scale Revised Version 2; PGI-C, Patient Global Impression of Change; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SE-ADL, Schwab and England Activities of Daily Living.

Target journal: Frontiers in Neurology (MedRxiv)

Figure 3. Schedule of activities in PASADENA Part 2

	Week 56	Week 64	Week 72	Week 80	Week 88	Week 96	Week 100	Week 104	Withdrawal 3 months
MDS-UPDRS	~	~	~	~	~	~		~	~
MoCA	~			~				~	~
	~			~				~	~
PGI-C	~			~				~	~
SE-ADL	~			~				~	~
PDQ39	~							~	~
SCOPA-AUT	~			~				~	~
PDSS-2	~			~			~		
DaT-SPECT	~							~	
Digital biomarker*									
MRI [†]								~	
								~	

*Digital includes PASADENA Digital Motor Score, Patient Global Impression of Severity, Daily diary, Patient Assessment of Constipation Symptoms (PAC-SYM), EuroQol-5D (EQ-5D) and Hospital Anxiety and Depression Scale (HADS). †Magnetic resonance imaging (MRI) includes safety, diffusion tensor imaging (DTI), resting state and arterial spin labeling (ASL).

CGI-I, Clinical Global Impression of Improvement; DaT-SPECT, dopamine transporter imaging with single-photon emission computerized tomography; MDS-UPDRS, Movement Disorder Society – Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; PDQ-39, Parkinson's Disease Questionnaire – 39; PDSS-2, Parkinson's Disease Sleep Scale Revised Version 2; PGI-C, Patient Global Impression of Change; SCOPA-AUT, Scales for outcomes in Parkinson's disease autonomic dysfunction; SE-ADL, Schwab and England Activities of Daily Living.

Figure 4. Table of digital measures included in the Roche Parkinson's Disease Mobile Application v2

	ACTIVE TESTS							PASSIVE MONITORING			IN-CLINIC TESTS			
	Bradykinesia	esia Tremor/ Tremor Bradykinesia		Rigidity/ Postural Instability		891'1 1 ¹⁰ 11	Bradykinesia and Activities of Daily Living		Balance					
Draw A Shape	Dexterity	Hand Turning	Speech	Phonation	Postural Tremor	Rest Tremor	Balance	U-Turn	Cognitive 81e2 (SDMT)	Gait	Arm Swing & Tremor	Mobility & Sociability	Timed Up & Go	Berg Balance Scale
0	50	10	P	\Box	Š	Ļ	Ť	Ϋ́D	8	***	*	*	الم	Ť
	radykinesia Da Every 2 nd Day		Alterr	nating			y 2 nd Day)		814 Fortnightly	Daily	Daily	Daily	At selected visits	At selected visits

SDMT, Symbol Digit Modalities Test.

Target journal: Frontiers in Neurology (MedRxiv)

823

824

825

Table 1. PASADENA; MAO-B inhibitor-treated vs. treatment-naïve patients, and

PASADENA (all patients) vs. PPMI. Demographics and baseline disease characteristics

compared using the standardized mean difference

	PASADENA MAO-B inhibitor- treated patients (n=115)	PASADENA treatment-naïve patients (n=201)	SMD (CI)	PASADENA All patients (n=316)	PPMI PD patients (n=336)	SMD (CI)
Age, years mean (SD)	58.2 (9.00)	60.8 (9.00)	-0.290* (-0.520, -0.059)	59.90 (9.10)	61.30 (9.69)	0.166 (0.012, 0.320)
Gender Male, n (%) [†]	74 (64.3)	139 (69.2)	-0.048 (-0.156, 0.060)	213 (67.4)	220 (65.5)	-0.019 (-0.092, 0.053)
Years of education, mean (SD)	16.39 (5.20)	15.22 (4.80)	0.234 (0.006, 0.467)	15.65 (4.99)	15.53 (3.03)	-0.029 (-0.183, 0.125)
Time from diagnosis, months mean (SD)	11.96 (6.10)	9.06 (6.50)	0.461* (0.225, 0.689)	10.11 (6.50)	6.44 (6.30)	-0.573* (-0.730, -0.417)
H&Y Stage II, n (%) [†]	83 (72.2)	155 (77.1)	-0.049 (-0.150, 0.051)	238 (75.3)	197 (59.0)	-0.167 (-0.238, -0.096)
RBDSQ (SD)	3.51 (2.65)	3.43 (2.75)	0.031 (-0.199, 0.260)	3.46 (2.71)	4.14 (2.69)	0.250 (0.095, 0.405)
DaT-SPECT contralateral putamen (SD)	0.81 (0.24)	0.78 (0.25)	-0.102 (-0.331, 0.128)	0.80 (0.25)	0.68 (0.27)	-0.445* (-0.601, -0.289)
DaT-SPECT ipsilateral putamen (SD)	1.02 (0.30)	1.09 (0.33)	-0.194 (-0.421, 0.038)	1.06 (0.32)	0.96 (0.39)	-0.285* (-0.439, -0.129
MoCA (SD)	28.27 (1.96)	27.65 (2.04)	0.309* (0.076, 0.539)	27.87 (2.03)	27.24 (2.29)	-0.291* (-0.446, -0.136
SCOPA-AUT (SD)	7.71 (4.82)	8.25 (6.16)	-0.096 (-0.323, 0.136)	8.05 (5.71)	9.75 (6.23)	0.284* (0.128, 0.439)
MDS-UPDRS Total, mean (SD)	30.21 (11.96)	32.10 (13.20)	-0.150 (-0.378, 0.081)	31.41 (12.78)	32.63 (13.04)	0.094 (-0.059, 0.248)
MDS-UPDRS Part I, mean (SD)	4.49 (3.40)	4.68 (4.06)	-0.051 (-0.279, 0.180)	4.61 (3.83)	5.60 (3.93)	0.255* (0.100, 0.409)
MDS-UPDRS Part IA, mean (SD)	0.96 (1.54)	1.27 (1.67)	-0.195 (-0.422, 0.037)	1.16 (1.62)	1.27 (1.57)	0.071 (-0.083, 0.224)
MDS-UPDRS Part IB, mean (SD)	3.53 (2.50)	3.14 (2.93)	0.045 (-0.185, 0.273)	3.45 (2.78)	4.33 (3.10)	0.297* (0.142, 0.451)
MDS-UPDRS Part II, mean (SD)	5.19 (3.90)	5.41 (4.13)	-0.055 (-0.284, 0.174)	5.33 (4.04)	6.12 (4.20)	0.190 (0.036, 0.344)
MDS-UPDRS Part III, mean (SD)	20.53 (8.81)	22.01 (9.09)	-0.165 (-0.394, 0.065)	21.47 (9.00)	20.92 (8.88)	-0.062 (-0.216, 0.092)
MDS-UPDRS Part III Axial Symptoms, mean (SD) [†]	0.77 (0.50)	0.78 (0.57)	-0.004 (-0.233, 0.225)	0.78 (0.54)	0.68 (0.71)	-0.153 (-0.307, 0.001)
MDS-UPDRS Part III Bradykinesia, mean (SD)‡	9.91 (5.60)	10.48 (5.49)	-0.102 (-0.331, 0.127)	10.27 (5.53)	10.60 (5.60)	0.059 (-0.095, 0.212)
MDS-UPDRS Part III Rigidity, mean (SD) [‡]	3.90 (2.58)	4.17 (2.83)	-0.103 (-0.331, 0.128)	4.07 (2.74)	3.86 (2.61)	-0.078 (-0.232, 0.075)
MDS-UPDRS Part III Resting Tremors, mean	2.71 (2.77)	3.12 (2.74)	-0.147 (-0.377, 0.082)	2.97 (2.75)	2.58 (2.42)	-0.151 (-0.305, 0.003)

*Indicates not balanced covariates (>0.25 SMD). [†]For binary variables the table shows the difference in proportions. [‡]Part III subscores are defined as: Bradykinesia (sum of item 3.4, finger tapping; item 3.5, hand movements; item 3.6, pronation-supination movements of hands; item 3.7, toe tapping; item 3.8, leg agility; item 3.9, arising from chair; item 3.13, posture; and item 3.14, body bradykinesia); Rigidity (sum of item 3.3. [Neck, Upper Limbs and Lower Limbs]); Resting tremors (sum of item 3.17, rest tremor amplitude [Lip/Jaw, Upper Limbs and Lower Limbs] and item 3.18, constancy of tremor); and axial symptoms (sum of item 3.10, gait; item 3.11, freezing of gait; and item 3.12, postural stability). CI, confidence interval; DaT-SPECT, dopamine transporter single-photon emission computerized tomography; H&Y, Hoehn and Yahr; MAO-B, monoamine oxidase B; MDS-UPDRS, Movement Disorders Society – Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; PD, Parkinson's disease; PPMI, Parkinson's Progression Markers Initiative; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SCOPA-AUT, Scales for outcomes in Parkinson's disease autonomic dysfunction; SD, standard deviation; SMD, standardized mean difference.

References

828

829

830

831

832

833

834

835

836 837

838

839

- 1. Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized Delayed-
- 841 Start Trial of Levodopa in Parkinson's Disease. The New England journal of medicine.
- 842 2019;380(4):315-24.

- 2. Lang AE, Espay AJ. Disease Modification in Parkinson's Disease: Current Approaches, Challenges,
- and Future Considerations. Movement disorders: official journal of the Movement Disorder Society.
- 845 2018;33(5):660-77.
- 3. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of
- 847 axons. Annals of Neurology. 2010;67(6):715-25.
- 4. Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr
- 849 Dis Treat. 2008;4(4):743-57.
- 5. Bonnet AM. Involvement of Non-Dopaminergic Pathways in Parkinson's Disease. CNS Drugs.
- 851 2000;13(5):351-64.
- 852 6. Giguere N, Burke Nanni S, Trudeau LE. On cell loss and selective vulnerability of neuronal
- populations in Parkinson's disease. Front Neurol. 2018;9:455.
- 7. Lees AJ. The on-off phenomenon. Journal of neurology, neurosurgery, and psychiatry.
- 855 1989;Suppl:29-37.
- 856 8. Jenner P. Treatment of the later stages of Parkinson's disease pharmacological approaches now
- and in the future. Transl Neurodegener. 2015;4:3.
- 858 9. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for
- 859 patients with Parkinson's disease: concepts, assessment and related factors. Expert Review of
- Pharmacoeconomics & Outcomes Research. 2012;12(2):221-30.
- 10. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on
- treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov
- 863 Disord. 2019;34(2):180-98.
- 11. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. Safety and
- Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal
- 866 Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA neurology.
- 867 2018;75(10):1206-14.
- 12. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization
- 869 reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy
- 870 body disease. PloS one. 2011;6(4):e19338.
- 13. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease.
- Nature reviewsDisease primers. 2017;3:17013.
- 14. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for
- 874 Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor
- dysfunction. Acta Neuropathologica. 2009;117(6):613-34.
- 15. Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of
- alpha-synuclein pathology. Neuropathology and applied neurobiology. 2016;42(1):33-50.
- 16. Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in
- Parkinson's disease consists of crowded organelles and lipid membranes. Nature neuroscience.
- 880 2019;22(7):1099-109.
- 17. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in
- 882 Lewy bodies. Nature. 1997;388(6645):839-40.
- 18. Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, et al. The process of
- Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of
- 885 neurodegeneration. Proceedings of the National Academy of Sciences of the United States of
- 886 America. 2020;117(9):4971-82.
- 887 19. Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, et al. Widespread transneuronal
- 888 propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease.
- 889 J Exp Med. 2016;13(9):1759-78.
- 20. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein
- 891 transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York,
- 892 NY). 2012;338(6109):949-53.

- 893 21. Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, et al. Axonopathy in an alpha-
- 894 synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-
- terminal-truncated alpha-synuclein. The American journal of pathology. 2013;182(3):940-53.
- 896 22. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, et al. α-Synuclein propagates from
- mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. The
- 898 Journal of clinical investigation. 2011;121(2):715-25.
- 899 23. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and
- 900 neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proceedings of the
- 901 National Academy of Sciences of the United States of America. 2009;106(31):13010-5.
- 902 24. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of
- 903 pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-
- 904 synucleinopathy in mice. J Exp Med. 2012;209(5):975-86.
- 905 25. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-
- synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.
- 907 Neuron. 2011;72(1):57-71.
- 908 26. Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal Propagation
- of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron.
- 910 2019;103(4):627-41 e7.
- 911 27. Rey NL, Bousset L, George S, Madaj Z, Meyerdirk L, Schulz E, et al. alpha-Synuclein
- conformational strains spread, seed and target neuronal cells differentially after injection into the
- 913 olfactory bulb. Acta Neuropathol Commun. 2019;7(1):221.
- 28. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-
- 915 synuclein gene identified in families with Parkinson's disease. Science (New York, NY).
- 916 1997;276(5321):2045-7.
- 917 29. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus
- 918 triplication causes Parkinson's disease. Science (New York, NY). 2003;302(5646):841.
- 30. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between
- alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (London, England).
- 921 2004;364(9440):1169-71.
- 31. Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, et al. Genetic association between
- 923 alpha-synuclein and idiopathic Parkinson's disease. American journal of medical geneticsPart B,
- 924 Neuropsychiatric genetics : the official publication of the International Society of Psychiatric
- 925 Genetics. 2008;147B(7):1222-30.
- 32. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol.
- 927 2010;23(4):228-42.
- 928 33. Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson's disease and alpha-synuclein expression.
- 929 Movement disorders: official journal of the Movement Disorder Society. 2011;26(12):2160-8.
- 930 34. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in
- 931 subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med.
- 932 2008;14(5):501-3.
- 933 35. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term
- embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14(5):504-6.
- 935 36. Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, et al. Serotonergic pathology
- and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-
- 937 sectional study. The LancetNeurology. 2019;18(8):748-59.
- 938 37. Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, et al. In-vivo staging
- 939 of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. The
- 940 LancetNeurology. 2018;17(7):618-28.
- 38. Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting alpha-synuclein
- 942 for treatment of Parkinson's disease: mechanistic and therapeutic considerations. The
- 943 LancetNeurology. 2015;14(8):855-66.

- 39. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-
- 945 synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005;46(6):857-68.
- 946 40. Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, et al. Reducing C-terminal-
- 947 truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in
- Parkinson's disease-like models. The Journal of neuroscience : the official journal of the Society for
- 949 Neuroscience. 2014;34(28):9441-54.
- 950 41. Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, et al. Anti-alpha-synuclein
- 951 immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined
- viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun. 2017;5(1):7.
- 42. Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, et al. Alpha-synuclein
- 954 immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and
- 955 neurodegeneration. Cell reports. 2014;7(6):2054-65.
- 956 43. Kallab M, Herrera-Vaquero M, Johannesson M, Eriksson F, Sigvardson J, Poewe W, et al. Region-
- 957 Specific Effects of Immunotherapy With Antibodies Targeting alpha-synuclein in a Transgenic Model
- of Synucleinopathy. Front Neurosci. 2018;12:452.
- 959 44. Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, et al. First-in-human
- assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers.
- 961 Movement disorders: official journal of the Movement Disorder Society. 2017;32(2):211-8.
- 962 45. PPMI. A landmark study of Parkinson's disease. 2018 [Available from: https://www.ppmi-
- 963 info.org/.
- 46. Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, et al. Longitudinal Change
- of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers
- 966 Initiative Cohort. Movement disorders: official journal of the Movement Disorder Society.
- 967 2018;33(5):771-82.
- 968 47. ClinicalTrials.gov. NCT03100149: A study to evaluate the efficacy of prasinezumab
- 969 (RO7046015/PRX002) in participants with early Parkinson's disease (PASADENA) 2017 [updated
- 970 17/12/2019. Available from:
- 971 https://clinicaltrials.gov/ct2/show/NCT03100149?term=prasinezumab&draw=2&rank=1.
- 972 48. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement
- 973 Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
- 974 scale presentation and clinimetric testing results. Movement disorders: official journal of the
- 975 Movement Disorder Society. 2008;23(15):2129-70.
- 976 49. Taylor KI, Staunton H, Lipsmeier F, Nobbs D, Lindemann M. Outcome measures based on digital
- 977 health technology sensor data: data- and patient-centric approaches. NPJ Digit Med. 2020;3:97.
- 978 50. Lipsmeier F, Simillion C, Bamdadian A, Smith A, Schobel S, Gossens C, et al. Reliability, feasibility
- and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in
- people with Stage I and II Huntington's disease (HD). Neurotherapeutics. 2019;16(4):1350-90.
- 981 51. Marek K, Chowdhury S, Siderowf A, Coffey CS, Caspell-Garcia CJ, Simuni T, et al. The Parkinson's
- 982 progression markers initiative (PPMI) establishing a PD biomarker cohort. Ann Clin Transl Neurol.
- 983 2018;5(12):1460-77.
- 52. Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically
- 985 important differences for the experiences of daily living parts of movement disorder society-
- 986 sponsored unified Parkinson's disease rating scale. Mov Disord. 2017;32(5):789-93.
- 987 53. Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Prog
- 988 Neurobiol. 2011;95(4):629-35.
- 989 54. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, et al. The Parkinson's
- 990 progression markers initiative (PPMI) establishing a PD biomarker cohort. Ann Clin Transl Neurol.
- 991 2018;5(12):1460-77.
- 992 55. Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic
- 993 for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8
- 994 Suppl):S84-S90 e1.

- 995 56. Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind,
- 996 delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc
- analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
- 998 The LancetNeurology. 2011;10(5):415-23.
- 999 57. Parkinson Study G. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
- 1000 Arch Neurol. 2002;59(12):1937-43.
- 1001 58. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. Movement
- disorders: official journal of the Movement Disorder Society. 2015;30(11):1442-50.
- 1003 59. Mollenhauer B, Trautmann E, Sixel-Doring F, Wicke T, Ebentheuer J, Schaumburg M, et al.
- Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.
- 1005 Neurology. 2013;81(14):1226-34.
- 1006 60. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson
- 1007 Study Group. Arch Neurol. 1994;51(4):342-7.
- 1008 61. Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in
- 1009 Parkinson's disease. Transl Neurodegener. 2013;2(1):19.
- 1010 62. Qamar MA, Sauerbier A, Politis M, Carr H, Loehrer P, Chaudhuri KR. Presynaptic dopaminergic
- 1011 terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for
- dopaminergic basis? NPJ Parkinsons Dis. 2017;3:5.
- 1013 63. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA.
- 1014 2014;311(16):1670-83.
- 1015 64. Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS Scores Over Five Years in
- 1016 De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Movement
- 1017 disorders clinical practice. 2018;5(1):47-53.
- 1018 65. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, et al. Longitudinal evolution
- of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain: a journal of
- 1020 neurology. 2011;134(Pt 11):3290-8.
- 1021 66. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter
- binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med.
- 1023 2004;45(10):1694-7.
- 1024 67. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for
- objective assessment of Parkinson's disease. Movement disorders : official journal of the Movement
- 1026 Disorder Society. 2013;28(12):1628-37.
- 1027 68. Ossig C, Antonini A, Buhmann C, Classen J, Csoti I, Falkenburger B, et al. Wearable sensor-based
- objective assessment of motor symptoms in Parkinson's disease. J Neural Transm (Vienna).
- 1029 2016;123(1):57-64.
- 1030 69. F. Lipsmeier IFG, D. Wolf, T. Kilchenmann, A. Scotland, J. Schjodt-Eriksen, W.Y. Cheng, J.
- 1031 Siebourg-Polster, L. Jin, J. Soto, L. Verselis, M. Martin Facklam, F. Boess, M. Koller, M. Grundman, M.
- 1032 Little, A. Monsch, R. Postuma, A. Gosh, T. Kremer, K. Taylor, C. Czech, C. Gossens, M. Lindemann.
- 1033 Successful passive monitoring of early-stage Parkinson's disease patient mobility in Phase I
- 1034 RG7935/PRX002 clinical trial with smartphone sensors. MDS; Basel, Switzerland2017.
- 1035 70. Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, et al. Evaluation of
- smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's
- disease clinical trial. Movement disorders: official journal of the Movement Disorder Society.
- 1038 2018;33(8):1287-97.
- 1039 71. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of neurology,
- 1040 neurosurgery, and psychiatry. 2008;79(4):368-76.
- 1041 72. Wang N, Gibbons CH, Lafo J, Freeman R. alpha-Synuclein in cutaneous autonomic nerves.
- 1042 Neurology. 2013;81(18):1604-10.
- 1043 73. Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, et al. Skin nerve alpha-
- synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology. 2014;82(15):1362-9.